



Firm Advises IGM Biosciences, Inc. on \$230 Million Public Offering



CLIENT HIGHLIGHTS

December 17, 2020

On December 11, 2020, IGM Biosciences, Inc. announced the closing of its upsized underwritten public offering of 1,221,224 shares of its common stock, which includes the exercise of the underwriters' option to purchase additional shares in full, and pre-funded warrants to purchase 1,334,332 shares of its common stock. The public offering price of common stock was \$90 per share and the public offering price of each pre-funded warrant was \$89.99, with each pre-funded warrant having an exercise price of \$0.01. The aggregate gross proceeds to IGM from the offering were approximately \$230 million, before deducting the underwriting discounts and commissions and other offering expenses payable by IGM. Wilson Sonsini Goodrich & Rosati represented IGM in the transaction.

Jefferies, Stifel, Guggenheim Securities, and RBC Capital Markets acted as joint book-running managers for the offering, while Baird and Truist Securities acted as the lead managers.

The Wilson Sonsini team that advised IGM on the transaction includes [Ken Clark](#), [Tony Jeffries](#), [Jennifer Knapp](#), [Amanda Urquiza](#), [Anna Mascoli](#), [Jay Carter](#), and [Mary Chamaki](#).

For more information, please see IGM's [press release](#).